行情

XXII

XXII

22ND CENTURY
NASDAQ

实时行情|Nasdaq Last Sale

3.020
+0.100
+3.42%
盘后: 3.020 0 0.00% 16:18 09/22 EDT
开盘
2.930
昨收
2.920
最高
3.030
最低
2.900
成交量
101.86万
成交额
--
52周最高
6.07
52周最低
0.5626
市值
4.91亿
市盈率(TTM)
-21.8366
分时
5日
1月
3月
1年
5年
日晷与 22 世纪集团:哪种大麻股票更值得购买?
StockNews.com · 9小时前
2020 年大麻二酚市场规模超过 70 亿美元,预计 2021 年至 2027 年间复合年增长率将超过 35% - 财经新闻媒体
Palm Beach, FL - September 15, 2021 - FinancialNewsMedia.com News Commentary – The CBD isolate market has been growing even before the pandemic appeared. While some areas of the healthcare sector remain to be impacted, the CBD sales have increased since th...
MENAFN · 09/15 18:36
2021 年第四季度的顶级医药股
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.
Investopedia · 09/14 16:51
2021 年 9 月 13 日大麻股票的上涨和下跌
GAINERS: Cipher Pharms Inc (OTC:CPHRF) shares closed up 13.17% at $2.13 with an estimated market cap of $56.4M.
Benzinga · 09/13 20:43
22nd Century Group 的资本使用回报洞察
Benzinga Pro data, 22nd Century Group (AMEX:XXII) reported Q2 sales of $8.37 million. Earnings fell to a loss of $6.64 million, resulting in a 28.41% decrease from last quarter.
Benzinga · 09/07 15:30
Innate Pharma、Adagio 每周领先的医疗保健赢家、Acasti Pharma、Forte Biosciences
As September started, the healthcare stocks in the S&P 500 returned to post gains after a brief decline last week. Thanks mainly to health insurers, the S&P 500 Healthcare Sector Index
Seekingalpha · 09/04 02:37
MariMed、Hexo 和 Aurora 大麻是 2021 年 9 月 1 日的顶级大麻推动者
GAINERS: cbdMd, Inc. (AMEX:YCBD) shares closed up 9.3% at $2.35 with an estimated market cap of $135.8M.
Benzinga · 09/01 22:20
周一的大麻股票推动者
GAINERS: Rhinomed (OTC:RHNMF) shares closed up 10.77% at $0.29 with an estimated market cap of $73.9M.
Benzinga · 08/30 22:58
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解XXII最新的财务预测,通过XXII每股收益,每股净资产,每股现金流等数据分析22ND CENTURY近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测XXII价格均价为6.33,最高价位7.00,最低价为5.00。
EPS
机构持股
总机构数: 162
机构持股: 4,952.63万
持股比例: 30.43%
总股本: 1.63亿
类型机构数股数
增持
21
1,485.55万
建仓
36
310.25万
减持
36
376.76万
平仓
19
361.25万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
环保服务及设备
+0.91%
专业与商业服务
+1.21%
高管信息
Non-Executive Chairman/Independent Director
Nora Sullivan
President/Chief Operating Officer
Michael Zercher
Chief Executive Officer
James Mish
Chief Financial Officer
John Franzino
Vice President
John Brodfuehrer
Vice President - Research & Development
Juan Tamburrino
Director of Investor Relations/IR Contact Officer
Mei Kuo
Independent Director
Clifford Fleet
Independent Director
Anthony Johnson
Independent Director
Michael Koganov
Independent Director
Roger O'Brien
Independent Director
Richard Sanders
暂无数据
XXII 简况
22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

微牛提供22nd Century Group Inc(NASDAQ-XXII)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的XXII股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易XXII股票基本功能。